20:55 , Apr 11, 2019 |  BC Week In Review  |  Company News

ADDF expands Alzheimer's diagnostic accelerator into digital space

With an additional $15 million in funding, the Alzheimer's Drug Discovery Foundation (ADDF) launched an initiative within its Diagnostics Accelerator program to advance the development of digital tools for Alzheimer's disease and related dementias. The...
03:19 , Jan 19, 2018 |  BC Innovations  |  Strategy

After amyloid

As the Alzheimer’s field is slowly taking on the search for new targets outside of the β amyloid and tau hypotheses, researchers are ramping up exploration of new pathways and looking to the disease’s genetics...
18:09 , Oct 20, 2017 |  BC Week In Review  |  Company News

Axxam and Sanofi to optimize CNS compounds

Axxam S.p.A. (Milan, Italy) said last month it partnered with Sanofi (Euronext:SAN; NYSE:SNY) to optimize lead small molecules, discovered by Axxam , in development to treat CNS diseases. Research will be performed at Sanofi and...
07:00 , Jun 30, 2016 |  BC Innovations  |  Targets & Mechanisms

AChE revisited

Selina Koch and Mark Zipkin, Staff Writers  Neuro-Bio Ltd. has identified a peptide derived from AChE - the enzyme responsible for breaking down acetylcholine - and believes the fragment is the main pathological driver in...
08:00 , Mar 5, 2015 |  BC Innovations  |  Strategy

Adding Up for AD

A year after world health leaders set a goal to find a disease-modifying therapy for dementia by 2025, not-for-profit groups and academics are keeping the pressure on governments and industry to stay in the game...
07:00 , Jul 24, 2014 |  BC Innovations  |  Strategy

AD mission in the U.K.

The U.K. government is responding to calls for a dementia therapy by 2025 by securing nearly £120 million ($205 million) from U.K.-based organizations for a series of research initiatives that span R&D from discovery to...
00:04 , Jun 27, 2014 |  BC Extra  |  Politics & Policy

Non-profits push for drug repurposing for neurodegenerative diseases

The Michael J. Fox Foundation for Parkinson's Research and the Alzheimer's Drug Discovery Foundation urged not-for-profits, industry and legislators to create incentives for repurposing drugs for neurodegenerative diseases like Alzheimer's disease and Parkinson's disease. The...
07:00 , May 29, 2014 |  BC Innovations  |  Strategy

New York's biotech beginnings

New York has long produced top science but has struggled to retain and develop its own innovations. The city says it hopes a flurry of public-private partnerships, real estate developments and high-profile academic appointments will...
07:00 , Mar 20, 2014 |  BC Innovations  |  Tools & Techniques

Plasma lipids: harbingers of AD?

A panel of plasma lipids could represent a new diagnostic tool for identifying patients likely to develop Alzheimer's disease before symptoms appear, according to new clinical findings from a team of U.S. researchers. 1 Although...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

Alzheimer's Drug Discovery Foundation, Alzheimer's Society neurology news

The ADDF and the society partnered to provide $3 million to fund research in Alzheimer's disease and related dementias. The partners plan to fund projects up to $1.5 million focused on drug repurposing, leveraging existing...